Cargando…

Clinical impact of Ocrelizumab extended interval dosing during the COVID-19 pandemic and associations with CD19(+)B-cell repopulation

Detalles Bibliográficos
Autores principales:	Sahi, Nitin Kumar, Abidi, Syed Muhammad Ali, Salim, Omar, Abraham, Roby, Kalra, Seema, Al-Araji, Adnan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier B.V. 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474870/ https://www.ncbi.nlm.nih.gov/pubmed/34627005 http://dx.doi.org/10.1016/j.msard.2021.103287

Ejemplares similares

Extended interval dosing of ocrelizumab modifies the repopulation of B cells without altering the clinical efficacy in multiple sclerosis
por: Rodriguez-Mogeda, Carla, et al.
Publicado: (2023)

Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19
por: Rolfes, Leoni, et al.
Publicado: (2021)

CD19 Cell Count at Baseline Predicts B Cell Repopulation at 6 and 12 Months in Multiple Sclerosis Patients Treated with Ocrelizumab
por: Abbadessa, Gianmarco, et al.
Publicado: (2021)

CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis
por: Baker, David, et al.
Publicado: (2022)

Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic
por: Zanghì, Aurora, et al.
Publicado: (2022)

Longitudinal humoral response after SARS-CoV-2 vaccination in ocrelizumab treated MS patients: To wait and repopulate?
por: van Kempen, Z.L.E., et al.
Publicado: (2022)

Sustained Low Relapse Rate With Highly Variable B-Cell Repopulation Dynamics With Extended Rituximab Dosing Intervals in Multiple Sclerosis
por: Starvaggi Cucuzza, Chiara, et al.
Publicado: (2022)

Switch to ocrelizumab in MS patients treated with natalizumab in extended interval dosing at high risk of PML: A 96-week follow-up pilot study
por: Santiago-Setien, Pilar, et al.
Publicado: (2023)

Confirmation of CD19+ B-Lymphocyte Depletion Prior to Intake of the Second Dose of Ocrelizumab in Multiple Sclerosis Patients
por: Radmilo, Marija, et al.
Publicado: (2023)

COVID-19 in ocrelizumab-treated people with multiple sclerosis
por: Hughes, Richard, et al.
Publicado: (2021)

Ocrelizumab Depletes CD20(+) T Cells in Multiple Sclerosis Patients
por: Gingele, Stefan, et al.
Publicado: (2018)

The Problem of Repopulation
Publicado: (1917)

Ocrelizumab/rituximab: COVID-19 infection: 2 case reports
Publicado: (2021)

COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab
por: Buttari, Fabio, et al.
Publicado: (2021)

Alemtuzumab/natalizumab/ocrelizumab: COVID-19: 3 case reports
Publicado: (2021)

Safety with Ocrelizumab in Rheumatoid Arthritis: Results from the Ocrelizumab Phase III Program
por: Emery, Paul, et al.
Publicado: (2014)

Anti-CD20 Agents for Multiple Sclerosis: Spotlight on Ocrelizumab and Ofatumumab
por: Florou, Despoina, et al.
Publicado: (2020)

Role of CD20(+) T cells in multiple sclerosis: implications for treatment with ocrelizumab
por: Gingele, Stefan, et al.
Publicado: (2019)

COVID-19 Vaccine Failure in a Patient with Multiple Sclerosis on Ocrelizumab
por: Chilimuri, Sridhar, et al.
Publicado: (2021)

Hypogammaglobulinemia, infections and COVID-19 in people with multiple sclerosis treated with ocrelizumab
por: Habek, Mario, et al.
Publicado: (2022)

A comparative study of tolerability and effects on immunoglobulin levels and CD19 cell counts with ocrelizumab vs low dose of rituximab in multiple sclerosis
por: Evertsson, Björn, et al.
Publicado: (2020)

Ocrelizumab-Induced Severe Colitis
por: Lee, Hsing Hwa, et al.
Publicado: (2020)

Anti-CD20 Cell Therapies in Multiple Sclerosis—A Fixed Dosing Schedule for Ocrelizumab is Overkill
por: Avasarala, Jagannadha
Publicado: (2017)

Influence of delaying ocrelizumab dosing in multiple sclerosis due to COVID-19 pandemics on clinical and laboratory effectiveness
por: Barun, Barbara, et al.
Publicado: (2021)

Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic
por: van Lierop, Zoë YGJ, et al.
Publicado: (2021)

Benign course of COVID-19 in a multiple sclerosis patient treated with Ocrelizumab
por: Suwanwongse, Kulachanya, et al.
Publicado: (2020)

Understanding the impacts of COVID-19 pandemic in people with multiple sclerosis treated with ocrelizumab
por: Pedotti, Rosetta, et al.
Publicado: (2021)

Critical Commentary: Repopulating density: COVID-19 and the politics of urban value
por: McFarlane, Colin
Publicado: (2021)

Ocrelizumab: A Review in Multiple Sclerosis
por: Lamb, Yvette N.
Publicado: (2022)

Tail Repopulation Measurements in the PSB
por: Benedetto, Elena, et al.
Publicado: (2017)

Repopulating glioma cell lines
por: Tuma, Rabiya
Publicado: (2004)

Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond?
por: Maarouf, Adil, et al.
Publicado: (2020)

COVID-19 in persons with multiple sclerosis treated with ocrelizumab – A pharmacovigilance case series
por: Hughes, Richard, et al.
Publicado: (2020)

COVID-19-Vaccine-Pfizer-BioNTech/ocrelizumab: Vaccine failure: case report
Publicado: (2021)

Extended-Interval Gentamicin Dosing for Pulmonic Tularemia
por: Dietrich, Tyson, et al.
Publicado: (2019)

Pharmacodynamics of natalizumab extended interval dosing in MS
por: Zhovtis Ryerson, Lana, et al.
Publicado: (2020)

Half-dose ocrelizumab in selected patients with relapsing–remitting multiple sclerosis
por: Algahtani, Hussein, et al.
Publicado: (2023)

Distribution and efficacy of ofatumumab and ocrelizumab in humanized CD20 mice following subcutaneous or intravenous administration
por: Torres, Julia Baguña, et al.
Publicado: (2022)

Evaluation of BAFF, APRIL and CD40L in Ocrelizumab-Treated pwMS and Infectious Risk
por: Zingaropoli, Maria Antonella, et al.
Publicado: (2023)

CD133 Is a Marker For Long-Term Repopulating Murine Epidermal Stem Cells
por: Charruyer, A, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_irermnr4e4tr8qq2il3lc1ifa4